For which diseases is anti-neutrophil cytoplasmic antibody (ANCA) testing used for diagnosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ANCA Testing: Primary Diagnostic Applications

ANCA testing is primarily used for diagnosing ANCA-associated vasculitides (AAV), which include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), as well as pauci-immune necrotizing crescentic glomerulonephritis. 1

Primary ANCA-Associated Diseases

Small-Vessel Vasculitides (Most Important)

Granulomatosis with Polyangiitis (GPA, formerly Wegener's granulomatosis):

  • PR3-directed c-ANCA is present in 80-90% of cases 2
  • Strongest association with ANCA positivity
  • Clinical features: persistent nasal bleeding, crusting, obstruction, septal perforation, pulmonary nodules, glomerulonephritis 2
  • ANCA can be negative in limited sinonasal disease, making diagnosis challenging 2

Microscopic Polyangiitis (MPA):

  • PR3-ANCA present in 20-40% of cases 2
  • MPO-ANCA more common (75-97% of cases) 3
  • Clinical features: rapidly progressive glomerulonephritis, alveolar hemorrhage 1

Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss syndrome):

  • ANCA positive in only 30-40% of patients 4
  • PR3-ANCA: 35% of cases 2
  • MPO-ANCA (p-ANCA): 35% of cases 2
  • Clinical features: adult-onset asthma, chronic rhinosinusitis with eosinophilic nasal polyps, peripheral neuropathy 2
  • ANCA testing should be performed in all suspected EGPA cases despite lower positivity rate 4

Pauci-Immune Necrotizing Crescentic Glomerulonephritis:

  • PR3-ANCA present in 20-40% of cases 2
  • Renal-limited form of microscopic polyangiitis 2

Secondary Associations (Lower Specificity)

Drug-Induced Vasculitis

  • Cocaine and levamisole (common cocaine adulterant) can cause ANCA-positive vasculitis 2
  • Various medications can induce ANCA positivity 2

Atypical c-ANCA (Different Antigenic Targets)

  • Cystic fibrosis: 80% positive (BPI as target antigen) 2
  • Inflammatory bowel disease 2
  • Primary sclerosing cholangitis 2
  • Rheumatoid arthritis 2

p-ANCA with Non-MPO Specificity

  • Inflammatory bowel disease 2
  • Autoimmune liver disease 2
  • Parasitic infections 2

Critical Testing Recommendations

Testing Methodology:

  • High-quality antigen-specific immunoassays for PR3-ANCA and MPO-ANCA are the preferred screening method 1, 3
  • Test for BOTH PR3-ANCA and MPO-ANCA simultaneously 3
  • If immunoassay negative but clinical suspicion high, perform second test (another immunoassay and/or indirect immunofluorescence) 3

Clinical Context Matters:

  • About 90% of patients with small-vessel vasculitis or NCGN have ANCA 1
  • ANCA negativity does NOT exclude AAV diagnosis 1, 3
  • 10-20% of GPA/MPA patients are ANCA-negative 5
  • 40-50% of EGPA cases are ANCA-negative 5

Important Clinical Pitfalls

Do Not Delay Treatment:

  • In clinical presentations compatible with small-vessel vasculitis with positive MPO- or PR3-ANCA serology, do not wait for kidney biopsy results before starting immunosuppressive therapy, especially in rapidly deteriorating patients 1

ANCA Alone Is Insufficient:

  • Diagnosis requires combination of clinical features, ANCA serology, and histopathology (necrotizing vasculitis, granulomatous inflammation) 2
  • ANCA can occur in other inflammatory diseases, infections, and drug-induced conditions 3, 6
  • Always correlate ANCA results with clinical presentation 7

Phenotype Associations:

  • MPO-ANCA in EGPA: associated with glomerulonephritis, neuropathy, purpura 4
  • ANCA-negative EGPA: more frequent cardiomyopathy and lung involvement 4
  • PR3-ANCA vs MPO-ANCA have distinct genetic backgrounds and clinical manifestations 3

References

Related Questions

What does a positive cytoplasmic antineutrophil cytoplasmic antibody (c‑ANCA) indicate?
What does the antineutrophil cytoplasmic antibody (ANCA) test detect?
Should a 1.1 cm ovarian follicle be followed up with repeat ultrasound?
What is the recommended evaluation and management for a 10-year-old male with pubic pain, intermittent dysuria for 2–3 months, decreased appetite, and urine specific gravity of 1.015?
How should I manage a 10-month-old infant with a rectal temperature of 100.6 °F and two episodes of vomiting?
In a 55-year-old patient who suddenly develops tingling (paresthesia) in the thumb and thenar eminence, what is the most likely diagnosis?
In a young patient admitted with intracranial hemorrhage who has less than 50% carotid artery stenosis and no other cardiovascular risk factors, should a statin be initiated?
What is the appropriate management for stress‑induced vomiting with inability to tolerate oral intake?
What is the recommended obstetric management for a patient with a multiple gestation?
What are the common surgical complications in inflammatory bowel disease and how can they be prevented and managed?
What is the recommended antibiotic regimen for treating walking (atypical) pneumonia in a patient with a penicillin allergy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.